[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600321":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":88,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Pennington Biomedical Research Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CGM group","EXPERIMENTAL",null,[13],"Device: Abbot Freestyle Libre CGM",{"label":15,"type":16,"description":11,"interventionNames":11},"SMBG group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","Abbot Freestyle Libre CGM","Participants assigned to the CGM group will receive the Libre 2+ systems (Abbott Diabetes Care, Alameda, CA) upon randomization. This will include comprehensive training provided by a qualified healthcare professional. The training will cover detailed instructions on sensor placement, how to download and use the associated smartphone application, and guidance on interpreting the glucose data effectively. To ensure continuous and accurate monitoring, the CGM sensor will be routinely replaced every 14 days following randomization. Additionally, in the event of sensor detachment or loss, immediate replacement will be arranged to maintain uninterrupted glucose tracking. Regular sessions are conducted to analyze glucose trends, refine management strategies, and provide additional support or education on device usage.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Yun Shen, MD","CONTACT","+1 2253486652","yun.shen@pbrc.edu",[30],{"facility":5,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Baton Rouge","Louisiana","70808","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-91.18747,30.44332,{"lat":40,"lon":39},[43,44,47,49,51,53],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"name":45,"role":46,"phone":11,"phoneExt":11,"email":11},"Peter T Katzmarzyk, PhD","SUB_INVESTIGATOR",{"name":48,"role":46,"phone":11,"phoneExt":11,"email":11},"Gang Hu, MD PhD MPH",{"name":50,"role":46,"phone":11,"phoneExt":11,"email":11},"Zubaidah Nor Hanipah, MD",{"name":52,"role":46,"phone":11,"phoneExt":11,"email":11},"Phillip R Schauer, MD",{"name":54,"role":46,"phone":11,"phoneExt":11,"email":11},"Jean Domercant, MD",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Yun Shen","Assistant professor",[60],{"name":61,"class":62},"LA CaTS Clinical Research Resources Core","UNKNOWN","100600321","continuous-glucose-monitoring-in-metabolic-surgery-100600321",false,"NCT07095972","Continuous Glucose Monitoring in Metabolic Surgery","Optimizing Glycemic Control in Metabolic Surgery With Continuous Glucose Monitoring","Inclusion criteria: (1) age 18 to 65 years; (2) body mass index (BMI) ≥35 kg\u002Fm2\n\nExclusion Criteria:\n\n(1) age \\\u003C18 or \\>65 years; (2) confirmed type 1 diabetes; (3) pregnancy or breastfeeding; (4) history of hypersensitivity to any of the components of the subcutaneous infusions; (5) without access at home to a telephone or other factor likely to interfere with ability to participate reliably in the study; (6) history of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer; (7) patients on insulin therapy before surgery; and (8) patients receiving revisional surgery.","ALL","18 Years","65 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"NA","We will recruit 20 severely obese participants at Metamor Institute. Participants with obesity who are eligible for MBS will be randomized to either CGM group or self-monitoring of blood glucose (SMBG) group before the surgery based on a 1:1 ratio. All participants live in Baton Rouge, Louisiana. The surgeon in Metamor will introduce our study to the patients. If the patients are interested, the evaluation process includes verifying basic personal information, assessing health status and medical history, and evaluating specific eligibility criteria relevant to the study. The study coordinator will be discussing informed consent, ensuring participants understand the study's purpose, procedures, and any associated risks or benefits. Participants are encouraged to ask questions, ensuring clarity and comfort with the study. All collected data is documented and securely stored, respecting data privacy protocols. Eligible individuals are informed about the screening visit, while those not suitable are considered for future studies.",[81],"Obesity (Disorder)",[83,84,85,86,87],"Severe Obesity","Metabolic Surgery","Continuous Glucose Monitoring","Post-Bariatric Hypoglycemia","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-24",{"date":91,"type":92},"2026-06-25","ACTUAL",{"date":94,"type":75},"2026-07-15",{"date":96,"type":75},"2027-05-31",{"name":5,"class":6},1]